<DOC>
	<DOCNO>NCT01865045</DOCNO>
	<brief_summary>This multicenter retrospective analysis .The aim present study investigate molecular predictor vinorelbine response tumor sample series MPM patient evaluate possible impact clinical outcome . Sample size : around 150 patient base availability tumor size</brief_summary>
	<brief_title>Pharmacogenetics Of Vinorelbine In Malignant Pleural Mesothelioma Patients</brief_title>
	<detailed_description>Vinorelbine recently become alternative option palliation select pemetrexed-pretreated patient malignant pleural mesothelioma ( MPM ) . However , nowadays definitive data vinorelbine predictor response MPM patient . The identification molecular predictor effective therapy important maximizing therapeutic efficacy minimize useless treatment cancer patient . In oncology pharmacogenetic approach customize chemotherapy treatment accord individual well tumour genetic characteristic represent modern intriguing challenge . Recent study suggest expression level class III β-tubulin ( TUBB3 ) BRCA1 , related survival benefit vinorelbine chemotherapy among patient advance solid malignancy , especially non-small cell lung cancer . There data predictive factor vinorelbine MPM patient . The identification molecular predictor effective therapy may allow future development good therapy .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<criteria>MPM patient treat vinorelbine ≥ second line set retrospectively analyze Patients select base availability tumor tissue</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>